Key Takeaways
- Rexulti (brexpiprazole) is used as a medicaiton for depression, and for schizophrenia and Alzheimer-related agitation.
- It works by balancing dopamine and serotonin, similar to Abilify but with different receptor activity.
- A licensed psychiatric provider can help you manage Rexulti by monitoring your progress and adjusting your treatment plan as needed.
Rexulti (brexpiprazole) is a prescription mental health medication used to treat depression, schizophrenia, and agitation linked to Alzheimer’s disease. It falls under the drug class of atypical antipsychotic (second-generation antipsychotic) and serotonin-dopamine activity modulator (SDAM). If your current antidepressant isn’t working well enough, your provider may recommend Rexulti for depression as an add-on treatment.
Since it is often compared to Abilify and considered an alternative, understanding the differences between these medications, including how they work, their side effects, and approved uses, can help you make more informed treatment decisions.
What Conditions Does Rexulti Treat?
Rexulti is FDA-approved to treat depression (as an add-on), schizophrenia, and agitation related to Alzheimer’s disease in specific populations.
FDA-approved uses of Rexulti in the US
Rexulti is approved by the US Food and Drug Administration (FDA) for:
- Adjunctive treatment of major depressive disorder (MDD) in adults
- Schizophrenia in adults and adolescents ages 13 and older
- Agitation associated with dementia due to Alzheimer’s disease (approved in 2023)
This makes it the first medication specifically approved for Alzheimer-related agitation. It is not approved for general dementia-related psychosis outside of this condition.
Rexulti as an adjunct treatment for depression in adults
Rexulti for depression works as an add-on, not a standalone treatment. It's prescribed when an antidepressant alone hasn't produced an adequate response. A systematic review published in The International Journal of Neuropsychopharmacology found that adjunctive brexpiprazole improved response and remission rates in adults with MDD who had an inadequate response to antidepressants.
Please note that these results reflect study populations and may not apply to everyone. Exploring depression treatment options with your healthcare provider will give you a fuller picture of what's available.
Pediatric approval status and off-label use considerations
Rexulti is approved for schizophrenia in adolescents aged 13 and older, but is not approved for depression in younger populations. Any use outside FDA-approved indications is considered off-label and should be guided by your psychiatry provider.
Differences in Rexulti indications across age groups
Here's an overview of approved uses by adult vs. other populations:
How Does Rexulti Work Compared To Abilify?
Rexulti and Abilify both work by balancing dopamine and serotonin activity in the brain, but they differ in how strongly they act on specific receptors.
Rexulti and Abilify as serotonin-dopamine activity modulators
Both Rexulti (brexpiprazole) and Abilify (aripiprazole) are classified as atypical antipsychotics described clinically as dopamine partial agonists with serotonergic activity. Instead of fully increasing or blocking dopamine, they help stabilize it, supporting mood, motivation, and perception.
The effects on brain chemicals
Specifically, both drugs target dopamine D2 receptors as partial agonists and also act on serotonin receptors, including partial agonism at 5-HT1A and antagonism at 5-HT2A. In plain terms, they help rebalance brain chemicals involved in mood and emotional regulation.
Key differences in receptor activity and clinical effects
Research published in CNS Spectrums suggests brexpiprazole has stronger activity at certain serotonin or non-D2 receptors, including 5-HT1A, 5-HT2A, and alpha 1B receptors compared to aripiprazole (Abilify). This difference may influence tolerability and side effects, but it doesn't guarantee better outcomes.
The impact of half-life on how these medications work:
Rexulti has a half-life of 91 hours, meaning it stays in your system for several days. Per the FDA, Abilify can last even longer in some individuals, up to 146 hours. However, both support once-daily dosing. A longer half-life means the medication clears the body more gradually, which influences what happens when doses are missed or when a medication is stopped.
What are the Key Dosing and Efficacy Differences?
Rexulti and Abilify are both taken once daily, but dosing and response vary in different people based on factors like metabolism and condition.
Typical dosing ranges for Rexulti compared to Abilify
Both medications are taken orally once per day, with or without food. Specific starting doses, titration ranges, and maximum doses vary by indication and are detailed in each medication's FDA label.
Dose adjustments and titration over time
Dosing for both may be adjusted based on:
- Response to treatment
- Side effects
- Other medications (especially those affecting CYP2D6 or CYP3A4 enzymes)
Titration timelines are determined by individual tolerability and response, not a universal schedule. It may take several weeks.
Comparative effectiveness of Rexulti and Abilify
There are no direct head-to-head clinical trials comparing Rexulti with Abilify. A study in the Cochrane Database of Systematic Reviews (CDSR) shows that brexpiprazole is effective compared to placebo, with improved response and remission rates in people with depression who did not respond to antidepressants alone. However, research suggests these benefits are statistically significant but modest in size, meaning results can vary between individuals.
It also suggests brexpiprazole may be associated with lower rates of akathisia/restlessness compared to aripiprazole, although both medications carry risks such as weight gain and metabolic changes. Because these medications have not been directly compared in the same trials, you should be cautious in interpreting the differences between the two.
Factors that influence dose selection and response
Several factors shape how a provider selects a medication. These include:
- Metabolism and genetics
- Other medications
- Medical history
- Treatment goals
This means your current medications and your unique metabolic profile both influence your healthcare provider’s choice of drug and dose. Exploring mental health medication support can help you understand what questions to bring to that conversation.
What Side Effects and Boxed Warnings Should I Know?
Both Rexulti and Abilify carry various warnings that deserve attention. Knowing what to watch for helps you respond quickly if something doesn't feel right.
Common side effects associated with Rexulti
Common side effects include:
- Weight gain
- Restlessness (akathisia)
- Sleepiness or fatigue
Not everyone experiences these effects, and severity varies.
Serious risks and boxed warnings linked to Rexulti:
Rexulti includes FDA boxed warnings for:
- Increased risk of death in elderly patients with dementia-related psychosis
- Suicidal thoughts and behaviors associated with antidepressant use
These risks require close monitoring, especially during treatment changes. Abilify carries the same two categories of boxed warnings.
Differences in side effect profiles between Rexulti and Abilify
Side effect comparisons are limited because studies differ in design and populations.
Some differences in restlessness or metabolic effects may occur, but tolerability is highly individual.
Side effects that require immediate medical attention
Contact your healthcare provider right away if you notice:
- Severe muscle stiffness or fever
- Uncontrolled movements
- Sudden mental status changes
These may signs of rare but serious reactions.
Who is Rexulti Right for, and When Might Abilify Be Preferred?
Rexulti may be a good option for adults with depression who need an add-on treatment, while Abilify may be preferred in certain pediatric or bipolar disorder-related cases. Whichever medication your doctor is considering, pairing it with therapy for depression can further support your recovery and overall mental well-being.
Patient profiles that may benefit most from Rexulti
Rexulti may be helpful for:
- Adults with depression not fully improved with antidepressants
- Individuals with schizophrenia
- Older adults with Alzheimer-related agitation (within approved use)
Situations where Abilify may be a more suitable option
Abilify may be preferred when:
- Treating bipolar I disorder
- Treating certain pediatric conditions (e.g., autism-related irritability)
- Broader FDA-approved uses are needed
The impact of cost and insurance coverage on medication choice
Rexulti's unique Alzheimer's agitation indication may trigger different prior authorization criteria and utilization management requirements compared with Abilify. Checking with your insurance plan before filling a prescription is a practical first step.
The role of medical history in selecting the right treatment
Your medical history plays a central role in determining whether Rexulti or Abilify is a better fit for you. Healthcare providers consider factors like past response to medications, current health conditions, and any other treatments you’re taking to reduce risks and improve outcomes.
For example, a history of side effects, metabolic concerns, or sensitivity to certain medications may influence the choice, as can conditions like bipolar disorder or the need for pediatric treatment. By looking at the full picture, not just symptoms, your healthcare provider can recommend a treatment plan that’s safer, more personalized, and more likely to be effective.
How Should You Take Rexulti Safely?
Rexulti should be taken once daily as prescribed, with attention to consistency, interactions, and medical guidance when adjusting doses.
Daily usage guidelines for taking Rexulti correctly
Consistency helps maintain stable medication levels. Take Rexulti:
- Once daily
- At the same time each day
- With or without food
Important precautions and interaction risks to consider
Rexulti interacts with medications that affect liver enzymes (CYP2D6 and CYP3A4). Always share your full medication list with your healthcare provider, including supplements. Additionally, the pharmacists where you pick up your medication should also be able to answer any interaction or precaution questions you have.
Risks associated with stopping Rexulti suddenly
Stopping Rexulti without guidance may lead to symptom return or complications. Since it stays in your system for several days, changes in dosing take time to fully reflect in your system. This is why any tapering plan should come directly from your healthcare provider rather than being self-managed.
Proper steps to take if a dose of Rexulti is missed
If you miss a dose, follow your healthcare provider’s instructions. Do not double up doses unless specifically told to do so.
How Can Talkspace Support Patients Taking Medication?
Starting or adjusting a medication like Rexulti raises questions about dosing, side effects, and long-term expectations. Consistent access to a licensed psychiatric provider makes it easier to monitor progress and adjust your plan without waiting for in-person appointments.
Talkspace psychiatry connects you with psychiatric providers who can guide your care every step of the way. Ready to take control of your mental health journey? Get started with Talkspace today.
Frequently Asked Questions (FAQs)
Does Rexulti cause more weight gain than Abilify?
Rexulti may cause weight gain, but comparing it directly to Abilify is difficult due to differences in studies and populations. Your healthcare provider can help you understand your individual risk.
How long does Rexulti take to work for depression?
Rexulti may take several weeks to show noticeable effects when used for depression. Your timeline will depend on your dose, response, and overall treatment plan.
Can I drink alcohol while on Rexulti?
It is generally not recommended to drink alcohol while taking Rexulti, as alcohol can increase side effects such as drowsiness, dizziness, and impaired judgment. Combining the two may also worsen the symptoms the medication is intended to treat.
Is generic brexpiprazole available?
Yes, generic brexpiprazole is available in the U.S. It is marketed under its chemical name rather than a brand name, making it a more affordable alternative to Rexulti.
What should I do if I miss a dose of Rexulti?
If you miss a dose, follow your healthcare provider’s instructions and avoid doubling up. A pharmacist or a psychiatric provider can give guidance based on your schedule.
Sources
- U.S. Food and Drug Administration. Rexulti (brexpiprazole) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205422s014lbl.pdf.. 2025; Accessed April 6, 2026.
- U.S. Food and Drug Administration. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer’s disease. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease. 2023 May 11; Accessed April 6, 2026.
- Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2019;22(11):698-709. doi:10.1093/ijnp/pyz040. https://pmc.ncbi.nlm.nih.gov/articles/PMC6872963/. Accessed April 6, 2026.
- Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectrums. https://www.cambridge.org/core/journals/cns-spectrums/article/mechanism-of-action-of-brexpiprazole-comparison-with-aripiprazole/410BABD1B670F753928441063F16D61B. 2016 Feb 22;21(1):1-6. Accessed April 6, 2026.
- U.S. Food and Drug Administration. Rexulti (brexpiprazole) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021436s046s050lbl.pdf. 2025 May. Accessed April 6, 2026.
- Martínez-Vélez NA, Escamilla Orozco RI, Flores Medina Y, et al. Aripiprazole versus brexpiprazole for people with schizophrenia. Cochrane Database Syst Rev. 2023;2023(2):CD014670. Published 2023 Feb 17. doi:10.1002/14651858.CD014670. https://pmc.ncbi.nlm.nih.gov/articles/PMC9936584/. Accessed April 6, 2026.
Talkspace articles are written by experienced mental health-wellness contributors; they are grounded in scientific research and evidence-based practices. Articles are extensively reviewed by our team of clinical experts (therapists and psychiatrists of various specialties) to ensure content is accurate and on par with current industry standards.
Our goal at Talkspace is to provide the most up-to-date, valuable, and objective information on mental health-related topics in order to help readers make informed decisions. Articles contain trusted third-party sources that are either directly linked to in the text or listed at the bottom to take readers directly to the source.
.jpg)
.jpg)
